Gland Pharma Limited has announced a strong financial performance for the financial year ending March 31, 2026. The company achieved a consolidated revenue growth of 14.5% and a consolidated adjusted profit after tax growth of 50%. Building on this success, the Board has recommended a final dividend of ₹20 per equity share, payable following shareholder approval at the upcoming 48th Annual General Meeting.
Consolidated Financial Performance
For the full financial year 2026, Gland Pharma reported a consolidated revenue of ₹64,307 million, representing a 14% increase over the previous year. The company’s consolidated adjusted PAT reached ₹10,455 million, marking a significant 50% year-on-year growth. For the fourth quarter ending March 31, 2026, the company posted revenue of ₹17,428 million, a 22% growth compared to the same period in the previous year, while adjusted PAT for the quarter rose by 97% to ₹3,667 million.
Dividend and Shareholder Meeting
Reflecting the company’s strong profitability, the Board of Directors has recommended a final dividend of ₹20 per equity share of ₹1 each. The record date for determining the eligibility of members to receive this dividend is set for Tuesday, August 11, 2026. The 48th Annual General Meeting of the company is scheduled to take place on Tuesday, August 25, 2026, via video conferencing.
Operational Highlights and Strategy
Management noted that the robust performance was driven by a combination of new product launches, a ramp-up in the CDMO business, and cost-efficiency initiatives. The company successfully launched 31 products in the USA during FY26, and its CDMO segment contributed 46% to the total revenue for the year. Looking ahead, the company continues to invest in its in-house complex pipeline and co-development partnerships to sustain its growth momentum and expand its presence in key global markets.
Source: BSE
